Table 1.
Baseline characteristics
| Linagliptin | Control | p-valuea | |||||
|---|---|---|---|---|---|---|---|
| Baseline | 3 months | Δ | Baseline | 3 months | Δ | ||
| Blood pressure systolic (mmHg) | 134 ± 17 | 142 ± 14 | 8 ± 18 | 128 ± 18 | 132 ± 18 | 4 ± 18 | 0.103 |
| Blood pressure diastolic (mmHg) | 79 ± 14 | 81 ± 12 | 1 ± 14 | 78 ± 10 | 78 ± 12 | 0 ± 14 | 0.599 |
| Low density lipoprotein (mg/dl) | 66 ± 31 | 80 ± 34 | 13 ± 43 | 76 ± 43 | 78 ± 43 | 4 ± 23 | 0.408 |
| Triglycerides (mg/dl), median (range) | 145 (54 to 480) | 132 (68 to 451) | − 16 (− 108 to 197) | 122 (63 to 255) | 146 (62 to 651) | 14 (− 16 to 396) | 0.173 |
| HbA1c (mmol/mol), median (range) | 50.5 (43 to 69) | 49 (38 to 88) | − 2 (− 8 to 27) | 51 (39 to 78) | 48 (39 to 71) | 0.5 (− 28 to 18) | 0.029 |
| Fasting blood glucose (mg/dl) | 136 ± 41 | 130 ± 39 | − 4 ± 18 | 123 ± 26 | 125 ± 36 | 4 ± 37 | 0.670 |
| Aspartate-aminotransferase (U/L) | 33.5 ± 14 | 34.9 ± 20.6 | 0.9 ± 21.9 | 27.6 ± 8.3 | 31.8 ± 12.9 | 4.7 ± 14.1 | 0.869 |
| Alanine-aminotransferase (U/L) | 40.4 ± 25 | 37.7 ± 21.7 | − 3.6 ± 21.4 | 29 ± 12.7 | 29.2 ± 11.9 | 1.0 ± 7.4 | 0.905 |
| Creatinine (mg/dL) | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.0 ± 0.1 | 1.0 ± 0.2 | 1.0 ± 0.2 | 0.0 ± 0.1 | 0.327 |
| eGFR (ml/min) | 76.7 ± 16.1 | 73.2 ± 17.6 | − 2.5 ± 11.4 | 80.8 ± 18.0 | 81.3 ± 17.5 | 0.5 ± 8.6 | 0.245 |
| NT-proBNP (pg/ml) | 419 ± 528 | 486 ± 519 | 65 ± 377 | 228 ± 452 | 232 ± 589 | 4 ± 192 | 0.543 |
| c-Reactive protein (mg/L) | 3.8 ± 4.2 | 2.4 ± 3.0 | − 1.5 ± 2.5 | 7.6 ± 20.4 | 3.3 ± 4.5 | − 4.6 ± 21.2 | 0.548 |
eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro b-type natriuretic peptide
ap values based on analysis of covariance except for triglycerides and HbA1c (Mann–Whitney-U-test for differences). Δ reflects difference between 3 months and baseline. Data are mean ± SD unless otherwise stated